Daniel A Harki

Daniel A Harki, Professor of Medicinal Chemistry at the University of Minnesota, is a leading researcher in cancer biology and molecular virology. Affiliated with the Institute for Molecular Virology, his work focuses on developing novel protein degraders for RET-positive cancers, targeting APOBEC mutagenesis in breast cancer, and creating antiviral compounds for RNA viruses.

• Current projects include NIH-funded studies on Neuroendocrine Prostate Cancer and Cancer Center Support
• Active member of multidisciplinary collaborations across the University of Minnesota's medical and molecular research divisions

His research portfolio spans biochemistry, enzymology, and chemical biology, with recent publications examining:

• Allosteric binding site targeting in NF-κB signaling
• Structure-activity relationships in Aurora kinase A degraders
• Sugar conformation effects on APOBEC3A/3B activity
• SARS-CoV-2 nucleocapsid protein inhibition
• West Nile/Zika virus nucleoside prodrugs

Key collaborations include co-investigator roles in 20 major projects and principal investigator positions on APOBEC Mutagenesis grants. His work contributes to UN Sustainable Development Goals through cancer research and antiviral development.